Education
About Us
Working with TipRanks
Follow Us
Cryo-Cell International (CCEL)
:CCEL
RESEARCH TOOLSreports
CCEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.96 - $9.50
Previous CloseN/A
Volume3.40K
Average Volume (3M)15.18K
Market Cap
$44.52M
Enterprise Value$79.51M
Total Cash (Recent Filing)$223.12K
Total Debt (Recent Filing)$5.41M
Price to Earnings (P/E)440.6
Beta0.25
Next Earnings
Jul 11, 2025EPS Estimate
-0.04Last Dividend Ex-Date
Feb 14, 2025Dividend Yield9.08%
Share Statistics
EPS (TTM)0.01
Shares Outstanding8,082,159
10 Day Avg. Volume13,077
30 Day Avg. Volume15,182
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.66
Price to Cash Flow (P/CF)6.20
P/FCF Ratio3.50
Enterprise Value/Market Cap1.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.31
Enterprise Value/Ebitda27.92
Forecast
1Y Price Target
$8.50Price Target Upside40.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
DividendsThe company initiated a $0.25 quarterly dividend, representing a 14.9% annualized yield.
Financial PerformanceCryo-Cell's core business of processing and storing stem cells has high margins of 79.6% gross and is mostly recurring.
Growth PotentialThe company has the capability to fund growth initiatives and the dividend from cash flows from operations and access to a $10M line of credit.
Bears Say
Business StrategyThe company paused plans to spin-off its drug trial and clinic businesses and stopped investing in those businesses due to a demand for arbitration against partner Duke University.
Financial EstimatesHigher litigation expenses and Duke royalty expenses have led to a reduction in financial estimates.
Litigation CostsHigher expenses are expected due to litigation costs and Duke royalty expenses being accrued.
---
Ownership Overview
33.49% Insiders
1.90% Mutual Funds
5.07% Other Institutional Investors
57.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CCEL FAQ
What was Cryo-Cell International ’s price range in the past 12 months?
Cryo-Cell International lowest stock price was $4.96 and its highest was $9.50 in the past 12 months.
What is Cryo-Cell International ’s market cap?
Cryo-Cell International ’s market cap is $44.52M.
When is Cryo-Cell International ’s upcoming earnings report date?
Cryo-Cell International ’s upcoming earnings report date is Jul 11, 2025 which is in 85 days.
How were Cryo-Cell International ’s earnings last quarter?
Currently, no data Available
Is Cryo-Cell International overvalued?
According to Wall Street analysts Cryo-Cell International ’s price is currently Undervalued.
Does Cryo-Cell International pay dividends?
Cryo-Cell International pays a Annually dividend of $0.5 which represents an annual dividend yield of 9.08%. See more information on Cryo-Cell International dividends here
What is Cryo-Cell International ’s EPS estimate?
Cryo-Cell International ’s EPS estimate is -0.04.
How many shares outstanding does Cryo-Cell International have?
Cryo-Cell International has 8,082,159 shares outstanding.
What happened to Cryo-Cell International ’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cryo-Cell International ?
Currently, no hedge funds are holding shares in CCEL
---
Cryo-Cell International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (40.96% Upside)
$8.50 (40.96% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.30%
12-Months-Change
Fundamentals
Return on Equity
93.38%
Trailing 12-Months
Asset Growth
4.33%
Trailing 12-Months
Company Description
Cryo-Cell International
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
---
CCEL Stock 12 Month Forecast
Average Price Target
$8.50
▲(40.96% Upside)
Technical Analysis
CytomX Therapeutics
―
Microbot Medical
―
Shattuck Labs
―
Kronos Bio
―
Gain Therapeutics
―
Best Analysts Covering CCEL
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+14.51%
reiterated a buy rating 2 days ago
Copying Allen Klee's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +14.51% per trade.
---